Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights

Initial update for NKX019 in multiple autoimmune indications expected in second half of 2025 Cash balance of $334.0 million on June 30, 2025, including cash, cash equivalents and investments, expected to fund operations into 2029 SOUTH SAN FRANCISCO, Calif., Aug.